Skip to main content
Clinical Trials/ACTRN12611000429954
ACTRN12611000429954
Active, not recruiting
未知

ongitudinal outcomes of hearing-impaired children: early versus later identification

ational Acoustic Laboratories, Australian Hearing0 sites468 target enrollmentApril 27, 2011

Overview

Phase
未知
Intervention
Not specified
Conditions
Hearing loss
Sponsor
ational Acoustic Laboratories, Australian Hearing
Enrollment
468
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 27, 2011
End Date
TBD
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
ational Acoustic Laboratories, Australian Hearing

Eligibility Criteria

Inclusion Criteria

  • Children in New South Wales, Victoria and Queensland who were born between 2002 and 2007, and who presented for hearing services at specialist paediatric hearing centres of Australian Hearing before 3 years of age.
  • Eligible participants will be deemed healthy.

Exclusion Criteria

  • Children who were over 3 years of age when they first received services from Australian Hearing.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Prevention of Bone loss in HIV-infected patients taking Highly Active Antiretroviral Therapy with ZoledronateHIV-related osteopeniaHIV-related osteoporosisInflammatory and Immune System - Acquired immune deficiency syndrome (AIDS / HIV)Musculoskeletal - Osteoporosis
ACTRN12605000208606Associate Professor A Grey70
Active, not recruiting
Phase 1
A randomised controlled trial to evaluate the feasibility of administering a drug called desmopressin to Intensive Care patients prior to procedures or radiological interventions, for prophylaxis against bleeding.
EUCTR2016-001126-33-GBHS Blood and Transplant40
Active, not recruiting
Not Applicable
Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% Nicotinamide combined with either 0%, 0.5% or 1.0% GMCY with the placebo cream.Seborrhoeic Dermatitis.
EUCTR2006-005637-37-GBAstion Danmark A/S
Completed
Not Applicable
A randomized, placebo-controlled, double blind human trial into the effect of Protecflor on gastroenteritis caused by attenuated E. Coligastroenteritistraveler's diarrhea1001796610004018
NL-OMON37365allemand Human Nutrition60
Active, not recruiting
Phase 1
A clinical trial to investigate the effect of a drug called CNV1014802 on intense face pain and how safe the drug is.Trigeminal NeuralgiaMedDRA version: 14.1Level: LLTClassification code 10029227Term: Neuralgia trigeminalSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2010-023963-16-LVConvergence Pharmaceuticals Ltd40